5UHY
| A Human Antibody Against Zika Virus Crosslinks the E Protein to Prevent Infection | Descriptor: | ZV67 Fab chain 1, ZV67 Fab chain 2, envelope protein | Authors: | Hasan, S.S, Miller, A, Sapparapu, G, Fernandez, E, Klose, T, Long, F, Fokine, A, Porta, J.C, Jiang, W, Diamond, M.S, Crowe Jr, J.E, Kuhn, R.J, Rossmann, M.G. | Deposit date: | 2017-01-12 | Release date: | 2017-03-29 | Last modified: | 2019-11-27 | Method: | ELECTRON MICROSCOPY (6.2 Å) | Cite: | A human antibody against Zika virus crosslinks the E protein to prevent infection. Nat Commun, 8, 2017
|
|
5CGY
| |
5KW9
| |
5CHN
| |
4XNM
| Antibody Influenza H5 Complex | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, H5.3 FAB Heavy Chain, H5.3 FAB Light Chain, ... | Authors: | Winarski, K.L, Spiler, B.W. | Deposit date: | 2015-01-15 | Release date: | 2015-07-15 | Last modified: | 2024-10-23 | Method: | X-RAY DIFFRACTION (2.51 Å) | Cite: | Vaccine-elicited antibody that neutralizes H5N1 influenza and variants binds the receptor site and polymorphic sites. Proc.Natl.Acad.Sci.USA, 112, 2015
|
|
4XNQ
| Antibody hemagglutinin Complexes | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, H5.3 Light chain, H5.3 heavy chain, ... | Authors: | Spiller, B.W, Winarski, K.L. | Deposit date: | 2015-01-15 | Release date: | 2015-07-15 | Last modified: | 2024-11-06 | Method: | X-RAY DIFFRACTION (2.001 Å) | Cite: | Vaccine-elicited antibody that neutralizes H5N1 influenza and variants binds the receptor site and polymorphic sites. Proc.Natl.Acad.Sci.USA, 112, 2015
|
|
4GSD
| H5.3 Fab Structure | Descriptor: | H5.3 Fab Heavy Chain, H5.3 Fab Light Chain | Authors: | Spiller, B.W, Winarski, K.L. | Deposit date: | 2012-08-27 | Release date: | 2013-08-21 | Last modified: | 2024-04-03 | Method: | X-RAY DIFFRACTION (2.251 Å) | Cite: | Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza viruses. J.Clin.Invest., 123, 2013
|
|
5V2A
| Crystal structure of Fab H7.167 in complex with influenza virus hemagglutinin from A/Shanghai/02/2013 (H7N9) | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Heavy chain of H7.167 antibody, Hemagglutinin, ... | Authors: | Zhang, H, Zhu, X, Wilson, I.A. | Deposit date: | 2017-03-03 | Release date: | 2017-04-05 | Last modified: | 2023-10-04 | Method: | X-RAY DIFFRACTION (4.656 Å) | Cite: | H7N9 influenza virus neutralizing antibodies that possess few somatic mutations. J. Clin. Invest., 126, 2016
|
|
4HFW
| Anti Rotavirus Antibody | Descriptor: | 6-26 Fab Heavy chain, 6-26 Fab Light chain, SULFATE ION | Authors: | Spiller, B.W, Aiyegbo, M, Crowe, J.E. | Deposit date: | 2012-10-05 | Release date: | 2013-05-29 | Method: | X-RAY DIFFRACTION (2.601 Å) | Cite: | Human Rotavirus VP6-Specific Antibodies Mediate Intracellular Neutralization by Binding to a Quaternary Structure in the Transcriptional Pore. Plos One, 8, 2013
|
|
4XRC
| Antibody hemagglutinin Complexes | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, H5.3 Fab heavy chain, H5.3 Fab light chain, ... | Authors: | Spiller, B.W, Winarski, K.L. | Deposit date: | 2015-01-20 | Release date: | 2015-07-15 | Last modified: | 2022-03-30 | Method: | X-RAY DIFFRACTION (2.74 Å) | Cite: | Vaccine-elicited antibody that neutralizes H5N1 influenza and variants binds the receptor site and polymorphic sites. Proc.Natl.Acad.Sci.USA, 112, 2015
|
|
4YAQ
| Crystal structure of a computationally optimized PG9 mutant | Descriptor: | 2-(N-MORPHOLINO)-ETHANESULFONIC ACID, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, PG9_N100FY Fab heavy chain, ... | Authors: | Murrell, S, Julien, J.P, Wilson, I.A. | Deposit date: | 2015-02-17 | Release date: | 2015-06-03 | Last modified: | 2024-11-06 | Method: | X-RAY DIFFRACTION (2.3 Å) | Cite: | Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth. J.Clin.Invest., 125, 2015
|
|